MedTrace Logo

Phase 1 Study of Relative Bioavailability of PPI-668 Tablet and Capsule Formulations

NCT01979484 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2014-01-09

No results posted yet for this study

Summary

This study will compare the blood levels of PPI-668 resulting from two different formulations - the current capsule and a new tablet.

Conditions

  • Pharmacokinetic Assessments in Healthy Volunteers

Interventions

DRUG

PPI-668 capsule

DRUG

PPI-668 tablet

Sponsors & Collaborators

  • Presidio Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Nathaniel Brown, MD · Presidio Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2013-11-30
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01979484 on ClinicalTrials.gov